IP-10 as a Screening Tool to Optimize HIV Viral Load Monitoring in Resource-limited Settings

This is an Open Access article distributed under the terms of the Creative Commons AttributionNonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com IP-10 as a Screening Tool to Optimize HIV Viral Load Monitoring in Resource-

[1]  F. Barré-Sinoussi,et al.  Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset , 2016, PLoS pathogens.

[2]  P. Newton,et al.  Modelling the Impact and Cost-Effectiveness of Biomarker Tests as Compared with Pathogen-Specific Diagnostics in the Management of Undifferentiated Fever in Remote Tropical Settings , 2016, PloS one.

[3]  K. Bonner,et al.  Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  C. Ignacio,et al.  Pooled Nucleic Acid Testing to Detect Antiretroviral Treatment Failure in HIV-Infected Patients in Mozambique , 2015, Journal of acquired immune deficiency syndromes.

[5]  R. Paredes,et al.  Determinants of virological failure and antiretroviral drug resistance in Mozambique. , 2015, The Journal of antimicrobial chemotherapy.

[6]  F. Cowan,et al.  Finger Prick Dried Blood Spots for HIV Viral Load Measurement in Field Conditions in Zimbabwe , 2015, PloS one.

[7]  J. Assmus,et al.  IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy. , 2015, The Journal of infection.

[8]  D. Richman,et al.  Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals , 2014, PloS one.

[9]  G. Carcelain,et al.  Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study , 2014, BMC Infectious Diseases.

[10]  W. Preiser,et al.  Pooled HIV-1 Viral Load Testing Using Dried Blood Spots to Reduce the Cost of Monitoring Antiretroviral Treatment in a Resource-Limited Setting , 2013, Journal of acquired immune deficiency syndromes.

[11]  F. Barré-Sinoussi,et al.  Acute Plasma Biomarkers of T Cell Activation Set-Point Levels and of Disease Progression in HIV-1 Infection , 2012, PloS one.

[12]  B. Greijdanus,et al.  Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Linezolid in Patients with Multidrug-Resistant Tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.

[13]  Hao Wu,et al.  Plasma IP-10 is associated with rapid disease progression in early HIV-1 infection. , 2012, Viral immunology.

[14]  P. Ravn,et al.  A Simple Method to Quantitate IP-10 in Dried Blood and Plasma Spots , 2012, PloS one.

[15]  Beth Chaplin,et al.  Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  B. Chi,et al.  Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa , 2011, AIDS.

[17]  T. F. Rinke de Wit,et al.  Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa , 2011, Journal of acquired immune deficiency syndromes.

[18]  J. Hibbert,et al.  CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications , 2011, Cytokine & growth factor reviews.

[19]  Guido Ferrari,et al.  Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy , 2011, PloS one.

[20]  C. Williamson,et al.  Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression , 2010, AIDS.

[21]  L. Lynen,et al.  Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings , 2010, Current opinion in HIV and AIDS.

[22]  Mila Lebedeva,et al.  Induction of a Striking Systemic Cytokine Cascade prior to Peak Viremia in Acute Human Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed Responses in Acute Hepatitis B and C Virus Infections , 2009, Journal of Virology.

[23]  A. Neumann,et al.  IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection , 2006, Hepatology.